Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2022-06-09 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Correction Report). It details changes to previously granted stock options, including adjustments to the number of shares and the list of recipients due to resignations. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance).
2022-06-09 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously filed stock option grant. It details changes to the number of recipients and the number of shares granted due to employee turnover. Since this is a specific regulatory disclosure regarding corporate capital/equity structure changes (stock options) that does not fit into other categories like M&A or dividend announcements, it is classified as a Regulatory Filing.
2022-06-09 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of recipients and the total number of shares granted due to employee resignations. This type of filing is a standard regulatory disclosure regarding capital structure and equity compensation, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Remuneration Information' (which is typically for executive compensation disclosures in proxy statements).
2022-06-09 Korean
기타경영사항(자율공시)(MSD와 공동임상 및 의약품 지원 계약 체결)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Clinical Trial Collaboration and Supply Agreement' between TiumBio and MSD. It details a specific business partnership and clinical trial collaboration. Since it does not fit into specific categories like M&A (which usually implies corporate mergers/acquisitions) or specific financial reports, and it is a formal regulatory disclosure of a material business event, it is best classified as a general Regulatory Filing (RNS).
2022-06-02 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'TiumBio' (주식회사 티움바이오) covering the period from January 1, 2022, to March 31, 2022. It contains detailed financial information, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-16 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, purpose, and where the IR materials will be posted. Since it is an announcement of an event and the availability of materials rather than the presentation itself, and it fits the regulatory announcement format for corporate events, it is classified as a Regulatory Filing (RNS).
2022-05-03 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.